Impact of COVID-19 Pandemic on Asthma Exacerbations: Retrospective Cohort Study of over 500,000 Patients in a National English Primary Care Database
Overview
Affiliations
Background: Several countries reported a substantial reduction in asthma exacerbations associated with COVID-19 pandemic-related restrictions. However, it is not known if these early reported declines were short-term and if these have rebounded to pre-pandemic levels following easing of lockdown restrictions.
Methods: We undertook a retrospective, cohort study of all asthma patients in a national primary care database of almost 10 million patients, Optimum Patient Care Database (OPCRD), identified from January 1, 2010, to December 31, 2015, using a previously validated algorithm. We subsequently followed the identified cohort of asthma patients from January 1, 2016, to October 3, 2021, and identified every asthma exacerbation episode with a validated algorithm. To quantify any pandemic-related change in exacerbations, we created a control time-series (mean of 2016-2019) and then compared the change in exacerbation rate in 2020-2021 over quarterly periods when compared with the control period (the pre-pandemic period). We undertook overall and stratified analyses by age group, sex, and English region.
Findings: We identified 100,362 asthma patients (502,669 patient-years) from across England who experienced at least one exacerbation episode (298,390 exacerbation episodes during the entire follow-up). Except for the first quarter of 2020, the exacerbation rates were substantially lower (>25%) during all quarters in 2020-2021 when compared with the rates during 2016-2019 (39.7% (95% Confidence Interval (CI): 34.6, 44.9) in quarter-2, 2020; 46.5% (95%CI: 36.7, 56.4) in quarter-3, 2020; 56.3% (95%CI: 48.7, 63.9) in quarter-4, 2020; 63.2% (95%CI: 53.9, 72.5) in quarter-1, 2021; 57.7% (95%CI: 52.9, 62.4) in quarter-2, 2021; 53.3% (95%CI: 43.8, 62.8) in quarter-3, 2021).
Interpretation: There was a substantial and persistent reduction in asthma exacerbations across England over the first 18 months after the first lockdown. This is unlikely to be adequately explained by changes in health-seeking behaviour, pandemic-related healthcare service disruption, or any air-quality improvements.
Funding: Asthma UK, Health Data Research UK (HDR UK), Medical Research Council (MRC), National Institute for Health Research (NIHR).
Gleeson P, Morales K, Buckey T, Fadugba O, Apter A, Christie J J Allergy Clin Immunol Glob. 2024; 4(1):100348.
PMID: 39583037 PMC: 11585680. DOI: 10.1016/j.jacig.2024.100348.
Caid K, Tate M, Yousuf S, Jones L, Pesek R, Jefferson A J Allergy Clin Immunol Glob. 2024; 3(4):100340.
PMID: 39498233 PMC: 11533078. DOI: 10.1016/j.jacig.2024.100340.
Zheng Y, Lan L, Lu G, Gao Y Chin Med J Pulm Crit Care Med. 2024; 2(3):188-196.
PMID: 39403411 PMC: 11471091. DOI: 10.1016/j.pccm.2024.08.004.
Eusebe C, Dauger S, Leger P, Houdouin V, Renolleau S, Amat F Pediatr Pulmonol. 2024; 60(1):e27322.
PMID: 39400483 PMC: 11733709. DOI: 10.1002/ppul.27322.
Nopsopon T, Brown A, Hahn G, Rank M, Huybrechts K, Akenroye A Respir Med. 2024; 234:107802.
PMID: 39260678 PMC: 11588503. DOI: 10.1016/j.rmed.2024.107802.